Cargando…

1196. Influence of antibiotic use on the effectiveness and safety of immune checkpoint inhibitors in Japan

BACKGROUND: It has been reported that antibiotic use changes the gut microbiome and alters the outcome of treatment with immune checkpoint inhibitors (ICIs). However, in Asia, this has not been well studied, and there is insufficient evidence to support these reports. METHODS: In this study, we inve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minamishima, Takuya, Hida, Hirotake, Yamada, Kiyofumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776143/ http://dx.doi.org/10.1093/ofid/ofaa439.1381

Ejemplares similares

P1196: DIFFERENT MUTATIONS IN PATIENTS WITH PRIMARY LARGE B-CELL LYMPHOMA
por: Kamaeva, I., et al.
Publicado: (2022)

1196. Environmental Contamination of Rooms of Patients Harboring Multidrug-Resistant Organisms
por: Page, Alex M, et al.
Publicado: (2022)

191. The impact of antibiotic use on clinical outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Vafea, Maria Tsikala, et al.
Publicado: (2020)

1196. Is the Weekend Staff Really to Blame? Challenges in Isolation Compliance at an Academic Tertiary Care Center
por: Bassett, Sonia, et al.
Publicado: (2019)

PM346. Social defeat stress as juveniles impairs persistent social behaviors and neurogenesis
por: Noda, Yukihiro, et al.
Publicado: (2016)

PS134. A strategy for treating in deficits of social behaviors induced by exposure to social defeat stress as juveniles
por: Hasegawa, Sho, et al.
Publicado: (2016)

1196. Determining Risk Criteria for Direct Oral Penicillin Challenge in Hospitalized Adults with a History of Penicillin Allergy
por: Hamid, Lina, et al.
Publicado: (2023)

Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors
por: Patel, Priyanka, et al.
Publicado: (2021)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
por: Qu, Chang-Ju, et al.
Publicado: (2023)

1196. Serratia marcescens Strains Carrying bla(KPC-2) and bla(KPC-3) Carbapenemase Associated With Chronic Mechanical Ventilation
por: Fisher, Matthew, et al.
Publicado: (2018)

Epidemiological Characteristics of 1196 Patients with Spinal Metastases: A Retrospective Study
por: Wang, Feng, et al.
Publicado: (2019)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

1654. Evaluation of a rapid detection method of clarithromycin resistance genes in Mycobacterium avium using the Amplification Refractory Mutation System-Loop-Mediated Isothermal Amplification method
por: Inagaki, Takayuki, et al.
Publicado: (2020)

Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors
por: Nam, Yunju, et al.
Publicado: (2019)

172. Inpatient Antibiotic Prescribing Patterns Using the WHO Access Watch and Reserve (AWaRe) Classification in Okinawa, Japan: A Point Prevalence Survey
por: Patel, Payal K, et al.
Publicado: (2021)

FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy
por: Ring, Jennifer, et al.
Publicado: (2015)

Vacuum Stability in Test section 333, (R 1196, 14th May 1981)
por: Mathewson, A, et al.
Publicado: (1981)

Severe multi-year drought coincident with Hittite collapse around 1198–1196 bc
por: Manning, Sturt W., et al.
Publicado: (2023)

P14 A rare adverse event of eosinophilic fasciitis secondary to immune checkpoint inhibitor therapy
por: Byravan, Swetha, et al.
Publicado: (2023)

Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors
por: Hamada, Kazuyuki, et al.
Publicado: (2022)

THER-16. EFFICACY OF UPFRONT IMMUNE CHECKPOINT INHIBITORS IN LUNG CANCER BRAIN METASTASIS
por: Barnett, Addison, et al.
Publicado: (2019)

THER-14. INFLUENCE OF CLINICAL PARAMETERS ON THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES (NSCLCBM)
por: Lauko, Adam, et al.
Publicado: (2019)

135. Influence of Prescribers on Antibiotic Use among Skilled Nursing Care Residents in 29 U.S. Nursing Homes
por: Wilson, Brigid, et al.
Publicado: (2021)

217. Broad Spectrum Antibiotic use in Outpatient Parenteral Antibiotic Therapy (OPAT): Opportunities for Antibiotic Stewardship
por: Brenon, Jessa R, et al.
Publicado: (2020)

602. Intravenous Push Versus Intravenous Piggyback Administration of Cephalosporin Antibiotics: Impact on Safety, Workflow, and Cost
por: Lee, Ryan, et al.
Publicado: (2021)

Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial
por: Wada, Shuhei, et al.
Publicado: (2023)

158. National Cross-Sectional Study of Factors Influencing the Decision of Prescribing Penicillin as First Choice among Dentists in Japan
por: Koizumi, Ryuji, et al.
Publicado: (2021)

Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
por: Jiang, Shuai, et al.
Publicado: (2022)

1636. Risk of Latent Tuberculosis Reactivation in Patients Treated with Checkpoint Inhibitors Immunotherapy Compared to Other Anti-Cancer Therapies including Hematopoietic Cell Transplantation
por: Malek, Alexandre, et al.
Publicado: (2020)

Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors
por: Gong, Jian, et al.
Publicado: (2014)

Response to the Article on Antibiotics and Immune Checkpoint Inhibitors by Lin et al.
por: Cheung, Ka Shing, et al.
Publicado: (2022)

QUALITY OF LIFE IN OLDER ADULTS RECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPY
por: Hoogland, Aasha I, et al.
Publicado: (2019)

Safety of sequential immune checkpoint inhibitors after prior immune therapy
por: Awidi, Muhammad, et al.
Publicado: (2022)

62. PRESENCE OF EXTRACRANIAL TUMORS INFLUENCES RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN A PRE-CLINICAL MODEL OF MELANOMA BRAIN METASTASIS
por: Nayyar, Naema, et al.
Publicado: (2020)

178. Implementation of the Core Elements of Antibiotic Stewardship in Nursing Homes – National Healthcare Safety Network (NHSN), 2016–2018
por: Gouin, Katryna A, et al.
Publicado: (2020)

242. Seasonality in antibiotic use and resistance across multiple bacterial pathogens and antibiotic classes
por: Sun, Daphne S, et al.
Publicado: (2020)

717. Antibiotic treatment of Shiga toxin-producing Escherichia coli related gastroenteritis and the risk of hemolytic uremic syndrome: a population based matched case-control study in Japan
por: Myojin, Shota, et al.
Publicado: (2020)

1676. Evaluation of Antibiotic Overuse for Asymptomatic Bacteriuria in a Hospital with Low Baseline Antibiotic Use
por: Kernan, Bailey, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_plnu5l7v89lr1egsguo0mh3ajm